rss
Br J Ophthalmol 2004;88:708-713 doi:10.1136/bjo.2003.032250
  • Perspective

Cannabinoids and glaucoma

  1. I Tomida1,
  2. R G Pertwee2,
  3. A Azuara-Blanco1
  1. 1Department of Ophthalmology, Aberdeen Royal Infirmary, University of Aberdeen, UK
  2. 2Department of Biomedical Sciences, Institute of Medical Sciences, University of Aberdeen, UK
  1. Correspondence to: A Azuara-Blanco PhD FRCS(Ed), The Eye Clinic, Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, UK; Aazblancoaol.com
  • Accepted 4 October 2003

Abstract

Glaucoma is one of the leading causes of blindness in the world. In spite of the diverse therapeutic possibilities, new and better treatments for glaucoma are highly desirable. Cannabinoids effectively lower the intraocular pressure (IOP) and have neuroprotective actions. Thus, they could potentially be useful in the treatment of glaucoma. The purpose of this article is to provide the reader with an overview of the latest achievements in research into the potential use of cannabinoids for glaucoma.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.